Virginia Liberini1,2, Martin W Huellner2, Serena Grimaldi1, Monica Finessi1, Philippe Thuillier1,3, Alfredo Muni4, Riccardo E Pellerito5, Mauro G Papotti6,7, Alessandro Piovesan8, Emanuela Arvat9, Désirée Deandreis1. 1. Nuclear Medicine Unit, Department of Medical Sciences, University of Turin, 10126 Turin, Italy. 2. Department of Nuclear Medicine, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland. 3. Department of Endocrinology, University Hospital of Brest, 29200 Brest, France. 4. Department of Nuclear Medicine, S.S. Biagio e Antonio e C. Arrigo Hospital, 15121 Alessandria, Italy. 5. Department of Nuclear Medicine, AO Ordine Mauriziano di Torino, 10128 Turin, Italy. 6. Pathology Unit, City of Health and Science University Hospital, 10126 Turin, Italy. 7. Department of Oncology, University of Turin at Molinette Hospital, 10126 Turin, Italy. 8. Department of Endocrinology, A. O. U. Città della Salute della Scienza of Turin, 10126 Turin, Italy. 9. Oncological Endocrinology, Department of Medical Sciences, University of Turin, 10126 Turin, Italy.
Abstract
The NETTER-1 study has proven peptide receptor radionuclide therapy (PRRT) to be one of the most effective therapeutic options for metastatic neuroendocrine tumors (NETs), improving progression-free survival and overall survival. However, PRRT response assessment is challenging and no consensus on methods and timing has yet been reached among experts in the field. This issue is owed to the suboptimal sensitivity and specificity of clinical biomarkers, limitations of morphological response criteria in slowly growing tumors and necrotic changes after therapy, a lack of standardized parameters and timing of functional imaging and the heterogeneity of PRRT protocols in the literature. The aim of this article is to review the most relevant current approaches for PRRT efficacy prediction and response assessment criteria in order to provide an overview of suitable tools for safe and efficacious PRRT.
The NETTER-1 study has proven peptide receptor radionuclide therapy (PRRT) to be one of the most effective therapeutic options for metastatic pan class="Disease">neuroendocrine tumors (NETs), improving progression-free survival and overall survival. However, PRRT response assessment is challenging and no consensus on methods and timing has yet been reached among experts in the field. This issue is owed to the suboptimal sensitivity and specificity of clinical biomarkers, limitations of morphological response criteria in slowly growing tumors and necrotic changes after therapy, a lack of standardized parameters and timing of functional imaging and the heterogeneity of PRRT protocols in the literature. The aim of this article is to review the most relevant current approaches for PRRT efficacy prediction and response assessment criteria in order to provide an overview of suitable tools for safe and efficacious PRRT.
Authors: Wouter T Zandee; Tessa Brabander; Anela Blažević; Boen L R Kam; Jaap J M Teunissen; Richard A Feelders; Johannes Hofland; Wouter W de Herder Journal: J Clin Endocrinol Metab Date: 2019-04-01 Impact factor: 5.958
Authors: Christoph Wetz; I Apostolova; I G Steffen; F Hofheinz; C Furth; D Kupitz; J Ruf; M Venerito; S Klose; Holger Amthauer Journal: Mol Imaging Biol Date: 2017-06 Impact factor: 3.488
Authors: Rudolf A Werner; Lilja B Solnes; Mehrbod S Javadi; Alexander Weich; Michael A Gorin; Kenneth J Pienta; Takahiro Higuchi; Andreas K Buck; Martin G Pomper; Steven P Rowe; Constantin Lapa Journal: J Nucl Med Date: 2018-03-23 Impact factor: 10.057
Authors: Marianne E Pavel; John D Hainsworth; Eric Baudin; Marc Peeters; Dieter Hörsch; Robert E Winkler; Judith Klimovsky; David Lebwohl; Valentine Jehl; Edward M Wolin; Kjell Öberg; Eric Van Cutsem; James C Yao Journal: Lancet Date: 2011-11-25 Impact factor: 79.321
Authors: Kjell Oberg; Irvin M Modlin; Wouter De Herder; Marianne Pavel; David Klimstra; Andrea Frilling; David C Metz; Anthony Heaney; Dik Kwekkeboom; Jonathan Strosberg; Timothy Meyer; Steven F Moss; Kay Washington; Edward Wolin; Eric Liu; James Goldenring Journal: Lancet Oncol Date: 2015-09 Impact factor: 41.316
Authors: Lisa Bodei; Mark S Kidd; Aviral Singh; Wouter A van der Zwan; Stefano Severi; Ignat A Drozdov; Anna Malczewska; Richard P Baum; Dik J Kwekkeboom; Giovanni Paganelli; Eric P Krenning; Irvin M Modlin Journal: Eur J Nucl Med Mol Imaging Date: 2019-12-14 Impact factor: 9.236
Authors: Marta Opalińska; Karolina Morawiec-Sławek; Adrian Kania-Kuc; Ibraheem Al Maraih; Anna Sowa-Staszczak; Alicja Hubalewska-Dydejczyk Journal: Front Endocrinol (Lausanne) Date: 2022-08-15 Impact factor: 6.055
Authors: Deborah Theiler; Marco Cattaneo; Lawrence O Dierickx; Peter Igaz; Simona Grozinsky-Glasberg; Claire Bournaud; Thomas O'Dorisio; M Sue O'Dorisio; Damian Wild; Emanuel Christ; Guillaume P Nicolas Journal: Cancers (Basel) Date: 2021-12-15 Impact factor: 6.639